Navigation Links
Akili Interactive Labs Announces Partnership with Pfizer to Test Video Game in People at Risk of Alzheimer's Disease
Date:1/9/2014

BOSTON, Jan. 9, 2014 /PRNewswire/ -- Akili Interactive Labs Inc. ("Akili") announced today that it has entered into an agreement with Pfizer Inc. to test the ability of Akili's mobile video game platform ("Project EVO") to detect cognitive differences in healthy elderly people at risk of developing Alzheimer's disease. To Akili's knowledge this is the first time that a large pharmaceutical company will test the use of a mobile video game as a  clinical tool to determine early signs of neurodegenerative disease pathology. 

Under the agreement, Pfizer will conduct a clinical trial that will evaluate healthy elderly subjects with and without the presence of amyloid in their brains, as determined by Positron Emission Tomography (PET) imaging.  Approximately 100 individuals are expected to be enrolled with their cognitive abilities assessed both at baseline, and over the course of one month of game play. The goal of the trial is to investigate the Akili game as a biomarker or clinical endpoint for potential use in future Alzheimer's trials. 

The Akili video game platform is designed to quantify and improve the ability of individuals to deal with cognitive interference (distractions and interruptions), which impacts their ability to pay attention, plan and make decisions. Such deficits are common symptoms of many degenerative diseases like Alzheimer's, as well as psychiatric conditions such as ADHD, autism and depression. The underlying Akili platform technology originated from the laboratory of Adam Gazzaley, M.D., Ph.D. at the University of California, San Francisco and was the cover story of the journal Nature in September 2013. Dr. Gazzaley is a co-founder and Chief Science Advisor to Akili.

"It's great to have Pfizer as a partner in an area where there is a clear need for novel approaches. Our collaboration with Pfizer is an example of Akili's strategy of
'/>"/>

SOURCE Akili Interactive Labs Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA clears Accu-Chek Combo system - Roches new interactive insulin pump system for people with diabetes
2. How to Create Dynamic Interactive Social Learning Spaces
3. Med Ad News, PharmaLive and Pharmalot Announce the Pharma Interactive Conference in Princeton, NJ
4. AASLD Curriculum & Training (ACT) Launches With New Interactive HCV Education
5. Windsor Selects COMS Interactive Disease Management Program
6. Wacoms DTH-2242: An Ideal Interactive Pen and Touch Display Solution for Healthcare and Presentation Markets
7. ADL Data Systems Partners With COMS Interactive, LLC
8. CPhI Pharma Evolution to Address Practical Approaches to Process Analytical Technology in Interactive Interview with PAT Expert
9. New Interactive Map Highlights Safest Hospitals for Patients Receiving Patient-Controlled Analgesia, Features Hospitals That Monitor With Capnography
10. Torrance Memorial Medical Center Selects COMS Interactive
11. Explore the Secrets of Lean Pharma Leadership in Two Live Interactive Video Chats on CPhI PharmaEvolution.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Tegra Medical is very pleased to announce ... its new Chief Executive Officer.  Mark was promoted from his ... overseen the company,s four facilities in Massachusetts ... King joined Tegra Medical in 2012 with 20+ years of ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... the extracellular matrix for the endocrinology, oncology, dermatology, ... of patient dosing for a Phase 1 clinical ... human hyaluronidase enzyme (rHuPH20) as a subcutaneous (SC) ...
... (Nasdaq: ALXA ) today announced positive results ... loxapine). This Phase 3,clinical trial was conducted in ... 5 mg and 10 mg doses of AZ-004 met ... significant reduction in,agitation from baseline to the 2-hour post-dose ...
Cached Medicine Technology:Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme 2Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme 3Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 2Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 3Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 4Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 5Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 6Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 7Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 8Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 9Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 10
(Date:4/17/2014)... the first genetic variant specifically associated with the ... around 10-15 per cent of all breast cancer ... breast cancer sub-type, called invasive lobular carcinoma, gives ... this particular kind of breast cancer, which can ... today (Thursday) in the journal PloS Genetics ...
(Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
(Date:4/17/2014)... Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently ... issue of Nature Reviews Microbiology , one ... McCullers, a world-renowned infectious disease specialist, and chair ... of Tennessee Health Science Center, analyzed the epidemiology ... and 1968 pandemics, as well as more recent ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
(Date:4/17/2014)... BostonResearchers from Boston University School of Medicine (BUSM) ... alcohol consumption in an experimental model. The findings, ... and Alcohol Abuse , may lead to more ... alcohol is one of the leading causes of ... significant negative economic impact by limiting the productivity ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... called Katrina caused indelible havoc, visible by the huge numbers of ... victims’ lives.// The intangible consequences, not apparent on the face of ... mind of the survivors, torn by memories of the disaster, resulting ... ,The study has shown that nearly 15% ...
... Cancer Board has indicated that the Klein Government is all ... for early stage breast cancer.// The spokeswoman of the board, ... clinical trials in the United Kingdom before advising the $40,000-per-patient ... Herceptin is available to those patients who are in dire ...
... a little closer in understanding the evolution of the viruses ... more infectious to people. ,According to researchers ... strains from the common human influenza. This conclusion follows the ... flu viruses. This analysis will also aid scientists trace the ...
... According to trade sources, egg exports have been restarted ... dispatched its first egg shipment to Muscat.// ... February, all the countries around the world had stopped ... under control successfully by the several steps taken by ...
... Minister for Health Anbumani Ramadoss announced on Saturday that ... set up in the country and one of them ... by the Tamil Nadu State AIDS Control Society, Ramadoss ... ,Other routine activities would include blood extraction, ...
... prevent avian flu developed by a research institute in the ... paise per dose, amounting to less than a// cent, official ... Security Animal Disease Laboratory (HSADL), it is the first vaccine ... which has the technique for identifying the avian influenza virus ...
Cached Medicine News:Health News:Understanding the Evolution of Viruses a little more Clearly 2Health News:‘Bird flu-free’ India resumes egg expor 2Health News:Bird Flu Vaccine Developed in India Could be Available for 35 Paise per Dose 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: